NCT04089215View on ClinicalTrials.gov

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

June 11, 2019

Primary Completion Date

September 10, 2021

Study Completion Date

September 30, 2024

Conditions
Lymphoma, Non-HodgkinDiffuse Large B Cell LymphomaFollicular Lymphoma
Interventions
BIOLOGICAL

CD19-targeted Chimeric Antigen Receptor (CAR) T Cells

JWCAR029 be administered at dose level: 1 x 10\^8 CAR+T cells and 1.5 x 10\^8 CAR+T cells

Trial Locations (10)

Unknown

Beijing Cancer Hospital, Beijing

Beijing Friendship Hospital, Capital Medical University, Beijing

Beijing Hospital, Beijing

Peking Union Medical College Hospital, Beijing

Guangdong General Hospital, Guangzhou

The First Affiliated Hospital of Zhenzhou Universtity, Zhenzhou

Jiangsu Cancer Hospital, Nanjing

Shanghai East Hospital, Shanghai

Institute of Hematology&Hospital of Blood Disease CAMS, Tianjin

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Shanghai Ming Ju Biotechnology Co., Ltd.

INDUSTRY